• Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors • To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers • To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications Geneva, […]
Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection London, UK, 22 May 2024 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round. The additional investment […]
Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a […]
Financing co-led by new investors Canaan and Alpha Wave, and with participation by the Global BioAccess Fund and existing investor Novo Holdings Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces that it has successfully closed an […]
Scientific milestones achieved significantly ahead of schedule Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the completion of its £21.5m (US $28.5m) Series B financing, with a £6m (US $7.5m) financing extension. The syndicate comprised its Series B subscribing investors including CRT Pioneer Fund, Claris Ventures, 2Invest, […]
